Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6688119 | 0.88 | GAA (0.65) | RECQLGAADGKAEPHX2FAAH | |
| SCHEMBL6686527 | 0.84 | GAA (0.69) | RECQLGAADGKAEPHX2FAAH | |
| SCHEMBL6692510 | 0.84 | GAA (0.69) | RECQLGAADGKAEPHX2FAAH | |
| SCHEMBL7147577 | 0.84 | GAA (0.69) | RECQLGAADGKAEPHX2FAAH | |
| SCHEMBL21190217 | 0.84 | GAA (0.58) | RECQLGAADGKAFAAHPOLB | |
| SCHEMBL22019573 | 0.82 | RECQL (0.47) | RECQLGAADGKAEPHX2FAAH | |
| SCHEMBL2139337 | 0.82 | DGKA (0.67) | DGKAEPHX2TSHRDNM1ALDH1A1 | |
| SCHEMBL31388630 | 0.81 | GAA (0.69) | RECQLGAADGKAFAAHDNM1 | |
| SCHEMBL20564125 | 0.80 | DGKA (0.70) | DGKAEPHX2FAAHTSHRPOLB | |
| SCHEMBL5269856 | 0.80 | DGKA (0.70) | DGKAEPHX2FAAHTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200405870-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | RECQL 3762/4885GAA 2127/4885DGKA 3919/4885 |
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | RECQL 3762/4885GAA 2127/4885DGKA 3919/4885 |
| US-20200405870-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | RECQL 3762/4885GAA 2127/4885DGKA 3919/4885 |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | RECQL 3762/4885GAA 2127/4885DGKA 3919/4885 |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | RECQL 3762/4885GAA 2127/4885DGKA 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.